Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 534

2.

Identification of Therapeutic Vulnerabilities in Small Cell Neuroendocrine Prostate Cancer.

Corella AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, Kaipainen A, Nguyen HM, Sondheim D, Brown L, True LD, Lee JK, MacPherson D, Nghiem P, Gulati R, Morrissey C, Corey E, Nelson PS.

Clin Cancer Res. 2019 Dec 5. pii: clincanres.0775.2019. doi: 10.1158/1078-0432.CCR-19-0775. [Epub ahead of print]

PMID:
31806643
3.

Radium-223 mechanism of action: implications for use in treatment combinations.

Morris MJ, Corey E, Guise TA, Gulley JL, Kevin Kelly W, Quinn DI, Scholz A, Sgouros G.

Nat Rev Urol. 2019 Dec;16(12):745-756. doi: 10.1038/s41585-019-0251-x. Epub 2019 Nov 11. Review.

PMID:
31712765
4.

Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC.

Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, Miranti CK, Warfel NA.

Am J Clin Exp Urol. 2019 Aug 15;7(4):297-312. eCollection 2019.

5.

COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer.

Umbreen S, Banday MM, Jamroze A, Mansini AP, Ganaie AA, Ferrari MG, Maqbool R, Beigh FH, Murugan P, Morrissey C, Corey E, Konety BR, Saleem M.

Mol Cancer Ther. 2019 Nov;18(11):2111-2123. doi: 10.1158/1535-7163.MCT-19-0150. Epub 2019 Aug 29.

PMID:
31467179
6.

Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer.

Cao S, Ma T, Ungerleider N, Roberts C, Kobelski M, Jin L, Concha M, Wang X, Baddoo M, Nguyen HM, Corey E, Fazli L, Ledet E, Zhang R, Silberstein JL, Zhang W, Zhang K, Sartor O, Dong X, Flemington EK, Dong Y.

Oncogene. 2019 Nov;38(45):7060-7072. doi: 10.1038/s41388-019-0947-7. Epub 2019 Aug 13.

PMID:
31409897
7.

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.

Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC.

Sci Transl Med. 2019 Jul 31;11(503). pii: eaaw4993. doi: 10.1126/scitranslmed.aaw4993.

8.

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.

Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C.

J Clin Invest. 2019 Jul 30;130:4492-4505. doi: 10.1172/JCI128212.

9.

Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS.

J Clin Invest. 2019 Jul 16;130:4245-4260. doi: 10.1172/JCI127613.

10.

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.

Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E.

Eur Urol. 2019 Jun 19. pii: S0302-2838(19)30449-X. doi: 10.1016/j.eururo.2019.05.042. [Epub ahead of print]

PMID:
31227306
11.

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.

Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, Goode D, Papargiris M, Mural, Clouston D, Ryan A, Norden S, Corey E, Nelson PS, Isaacs JT, Grummet J, Kourambas J, Sandhu S, Murphy DG, Pook D, Frydenberg M, Taylor RA, Risbridger GP.

Prostate. 2019 Aug;79(11):1326-1337. doi: 10.1002/pros.23839. Epub 2019 Jun 18.

PMID:
31212368
12.

Lineage relationship between prostate adenocarcinoma and small cell carcinoma.

Kanan AD, Corey E, Vêncio RZN, Ishwar A, Liu AY.

BMC Cancer. 2019 May 30;19(1):518. doi: 10.1186/s12885-019-5680-7.

13.

Publisher Correction: A ribonucleoprotein octamer for targeted siRNA delivery.

Tai W, Li J, Corey E, Gao X.

Nat Biomed Eng. 2018 Aug;2(8):622. doi: 10.1038/s41551-018-0272-4.

PMID:
31015633
14.

A ribonucleoprotein octamer for targeted siRNA delivery.

Tai W, Li J, Corey E, Gao X.

Nat Biomed Eng. 2018 May;2(5):326-337. doi: 10.1038/s41551-018-0214-1. Epub 2018 Apr 2. Erratum in: Nat Biomed Eng. 2018 Aug;2(8):622.

PMID:
30936447
15.

A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer.

Bai S, Cao S, Jin L, Kobelski M, Schouest B, Wang X, Ungerleider N, Baddoo M, Zhang W, Corey E, Vessella RL, Dong X, Zhang K, Yu X, Flemington EK, Dong Y.

Oncogene. 2019 Jun;38(25):4977-4989. doi: 10.1038/s41388-019-0768-8. Epub 2019 Feb 28.

16.

Maternal age alters offspring lifespan, fitness, and lifespan extension under caloric restriction.

Bock MJ, Jarvis GC, Corey EL, Stone EE, Gribble KE.

Sci Rep. 2019 Feb 28;9(1):3138. doi: 10.1038/s41598-019-40011-z.

17.

Method for the Direct Enantioselective Synthesis of Chiral Primary α-Amino Ketones by Catalytic α-Amination.

Han Y, Corey EJ.

Org Lett. 2019 Jan 4;21(1):283-286. doi: 10.1021/acs.orglett.8b03733. Epub 2018 Dec 21.

PMID:
30576160
18.

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.

Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.

19.

High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.

Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, McKnight C, Klummp-Thomas C, Zhang X, Guha R, Hoover S, Simpson RM, Nguyen HM, Corey E, Thomas CJ, Proia DA, Kelly K.

Sci Rep. 2018 Nov 22;8(1):17239. doi: 10.1038/s41598-018-35417-0.

20.

Enantioselective Conversion of Oligoprenol Derivatives to Macrocycles in the Germacrene, Cembrene, and 18-Membered Cyclic Sesterterpene Series.

Reddy DS, Corey EJ.

J Am Chem Soc. 2018 Dec 12;140(49):16909-16913. doi: 10.1021/jacs.8b10522. Epub 2018 Nov 28.

PMID:
30466258

Supplemental Content

Loading ...
Support Center